Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium.
Han JX, Koh MJ, Boussi L, Sorial M, McCabe SM, Peng L, Singh S, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, MacVicar CT, Garg AR, Disciullo A, Chopra K, Lenart AW, Nwodo E, Barnes JA, Koh MJ, Miranda ECM, Chiattone CS, Stuver RN, Horwitz SM, Merrill MH, Jacobsen ED, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim YR, Kim JS, Cho JY, Eipe T, Shet T Dr, Epari S, Shetty A, Saha S, Jain H Dr, Sengar M MD, DM, Van Der Weyden C, Prince HM, Hamouche R, Muradashvili T, Foss FM, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, Kim WS, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Ford J, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Iwasaki M, Bhanushali F, O'Connor OA, Marchi E, Shen C, Shah D, Jain S.
Han JX, et al. Among authors: miranda ecm.
Blood Adv. 2024 Oct 31:bloodadvances.2024014674. doi: 10.1182/bloodadvances.2024014674. Online ahead of print.
Blood Adv. 2024.
PMID: 39481087